IP Library › Granted Patent US 12,180,491
Granted Patent B2
US 12,180,491 · App. 16/980,266 · Granted Dec 31, 2024

Plant expression enhancer

Inventors: Pierre-Oliver Lavoie (Quebec, CA); Marc-Andre D'Aoust (Quebec, CA); Ko Kato (Nara, JP); Shotaro Yamasaki (Nara, JP)
Assignee: ARAMIS BIOTECHNOLOGIES INC.
C12N15/8258C12N15/8203C12N15/8216C12N15/86C12N2760/16122C12N2760/16222C12N2770/16022C12N2770/16023C12N2770/18043
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,180,491
App. No.
16/980,266
Granted
Dec 31, 2024
Kind
B2
Abstract

An isolated expression enhancer active in a plant, portion of a plant or plant cell, the expression enhancer is provided. The isolated expression enhancer may be selected from the group consisting of nbMT78 (SEQ ID NO:1); nbATL75 (SEQ ID NO:2); nbDJ46 (SEQ ID NO:3); nbCHP79 (SEQ ID NO:4); nbEN42 (SEQ ID NO:5); atHSP69 (SEQ ID NO:6); atGRP62 (SEQ ID NO:7); atPK65 (SEQ ID NO:8); atRP46 (SEQ ID NO:9); nb30S72 (SEQ ID NO:10); nbGT61 (SEQ ID NO:11); nbPV55 (SEQ ID NO:12); nbPPI43 (SEQ ID NO:13); nbPM64 (SEQ ID NO:14); and nbH2A86 (SEQ ID NO:15). Methods for using the isolated expression enhancer are also provided.

Claims (22)

1. A nucleic acid comprising an expression enhancer operatively linked with a heterologous nucleotide sequence encoding a protein of interest, the expression enhancer consisting of:

nbMT78 (SEQ ID NO:1).

2. The nucleic acid of claim 1 , where the heterologous nucleotide sequence encodes a viral protein or an antibody.

3. The nucleic acid of claim 2 , wherein the viral protein is an influenza protein or a norovirus protein.

4. The nucleic acid of claim 3 , wherein the influenza protein is a hemagglutinin protein selected from the group of H1, H2, H3, H4, H5, H6, H7, H8, H9, H10, H11, H12, H13, H14, H15, H16, and an influenza type B hemagglutinin.

5. The nucleic acid of claim 3 , wherein the norovirus protein is a VP1, a VP2, or a combination thereof selected from the group of GI.1, GI.2, GI.3, GI.5, GI.7, GII.1, GII.2, GII.3, GII.4, GII.5, GII.6, GII.7, GII. 12, GII. 13, GII. 14, GII. 17 and GII.21.

6. A plant expression system comprising one or more than one of the nucleic acid of claim 1 .

7. A plant expression system comprising one or more than one of nucleic acid of claim 2 .

8. A plant expression system comprising one or more than one of the nucleic acid of claim 3 .

9. A plant expression system comprising one or more than one of the nucleic acid of claim 4 .

10. A plant expression system comprising one or more than one of the nucleic acid of claim 5 .

11. The plant expression system of claim 6 further comprising a comovirus 3′ UTR.

12. A method of producing a protein of interest in a plant, a portion of a plant, or a plant cell, comprising,

introducing into the plant, the portion of a plant, or the plant cell, in a stable or transient manner, the plant expression system of claim 7 comprising the one or more than one nucleic acid, and

incubating the plant or the portion of a plant under conditions that permit expression of each of the heterologous nucleotide sequence encoding the protein of interest.

13. The method of claim 12 , wherein the protein of interest is a viral protein.

14. The method of claim 13 , wherein the viral protein is an influenza protein or a norovirus protein.

15. The method of claim 14 , wherein the influenza protein is a hemagglutinin protein selected from the group of H1, H2, H3, H4, H5, H6, H7, H8, H9, H10, H11, H12, H13, H14, H15, H16, and an influenza type B hemagglutinin.

16. The method of claim 14 , wherein the norovirus protein is a VP1, a VP2, or a combination thereof selected from the group of GI.1, GI.2, GI,3, GI.5, GI.7, GII. 1, GII.2, GII.3, GII.4, GII.5, GII.6, GII.7, GII. 12, GII. 13, GII. 14, GII. 17 and GII.21.

17. The method of claim 12 , wherein the protein of interest is a multimeric protein, and the step of introducing involves co-expressing two or more than two of the nucleotide sequence, each of the two or more than two of the nucleotide sequence encoding a component of the multimeric protein.

18. A plant, portion of a plant, or a plant cell, transiently transformed or stably transformed with the plant expression system of claim 7 .

19. The nucleic acid of claim 1 , wherein the expression enhancer increases expression of the heterologous nucleotide sequence encoding the protein of interest in a Nicotiana benthamiana plant when compared to the level of expression of the same heterologous nucleotide sequence that is not operatively linked to the expression enhancer.

Assignments (7)
CORRECTIVE ASSIGNMENT TO CORRECT THE APPLICATION NO. 16908266 ON THE PATENT ASSIGNMENT COVERSHEET NEEDS TO BE CORRECTED TO 16980266 WHICH IS THE APPLICATION NUMBER ON THE ACTUAL ASSIGNMENT DOCUMENT PREVIOUSLY RECORDED ON REEL 68059 FRAME 100. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jul 25, 2024
From: MEDICAGO INC.
To: ARAMIS BIOTECHNOLOGIES INC.
Reel/Frame 068147/0820 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 23, 2024
From: MEDICAGO INC.
To: ARAMIS BIOTECHNOLOGIES INC.
Reel/Frame 068059/0100 →
CORRECTIVE ASSIGNMENT TO CORRECT THE CORRECT BOTH ASSIGNEE NAMES REPLACE THE PREVIOUSLY RECORDED ASSIGNMENT AND UPDATE THE EXECUTION DATES OF THE ASSIGNMENT PREVIOUSLY RECORDED ON REEL 065080 FRAME 0441. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Nov 30, 2023
From: NATIONAL UNIVERSITY CORPORATION NARA INSTITUTE OF SCIENCE AND TECHNOLOGY; MITSUBISHI TANABE PHARMA CORPORATION
To: MEDICAGO INC.
Reel/Frame 065776/0053 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 29, 2023
From: NARA INSTITUTE OF SCIENCE AND TECHNOLOGY; MITSUBISHI PHARMA CORPORATION
To: MEDICAGO INC.
Reel/Frame 065080/0441 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 11, 2022
From: KATO, KO; YAMASAKI, SHOTARO
To: NATIONAL UNIVERSITY CORPORATION NARA INSTITUTE OF SCIENCE AND TECHNOLOGY
Reel/Frame 058621/0346 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 11, 2022
From: MEDICAGO INC.; NATIONAL UNIVERSITY CORPORATION NARA INSTITUTE OF SCIENCE AND TECHNOLOGY
To: MITSUBISHI TANABE PHARMA CORPORATION; MEDICAGO INC.; NATIONAL UNIVERSITY CORPORATION NARA INSTITUTE OF SCIENCE AND TECHNOLOGY
Reel/Frame 058621/0365 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 11, 2022
From: D'AOUST, MARC-ANDRE; LAVOIE, PIERRE-OLIVIER
To: MEDICAGO INC.
Reel/Frame 058621/0274 →
Continuity (2)
Provisional Application 62643053 · Mar 14, 2018
Related Publication 20210246462A1 · Aug 12, 2021